Clinical Trends for September 2017

Ryan Syrek

Disclosures

September 29, 2017

Clinical Trend of the Week (September 2-8): Bacteria in Urine

Searches for "bacteria in urine" spiked this week in response to concerns about treatment resistance and a new tool approved to overcome that resistance. A recently published viewpoint discussed the various considerations when dealing with bacteria in the urine. Specifically, the article focused on an antibiotic stewardship program in long-term care facilities designed to help manage the significant prevalence of urinary tract infections (UTIs) in patients residing in those facilities. Often, patients and families urge treatment of bacteria in the urine, even if asymptomatic bacteruria should not be treated with antibiotics in order to prevent future resistance. The stewardship program is designed to help with that scenario. As far as UTIs that should be treated, the US Food and Drug Administration (FDA) just approved Vabomere, which combines the carbapenem antibacterial agent meropenem with vaborbactam. It is expected to be available in the fourth quarter of 2017 for the treatment of complicated UTIs. As the approach to bacteria in the urine continues to evolve, searches for the scenario will remain quite popular.

For more information on asymptomatic bacteruria, read here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....